• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Studies: Low-Dose Aspirin May Not Prevent Initial Heart Attack, Stroke
Taking a low-dose aspirin every day has long been known to cut the chances of another heart attack, stroke or other heart problem in people who already have had one, but the risks don’t outweigh the benefits for most other folks, major new research finds. Although it’s been used for more than a century, aspirin’s value in many situations is still unclear. The latest studies are some of the largest and longest to test this pennies-a-day blood thinner in people who don’t yet have heart disease or a blood vessel-related problem. One found that aspirin did not help prevent first strokes or heart attacks...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 27, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch aspirin Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

EPMA-World Congress 2015
Table of contents A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-Andrea Abraham, Olga Golubnitschaja A2 Integrated market access approach amplifying value of “Rx-CDx” Ildar Akhmetov A3 Disaster response: an opportunity to improve global healthcare Russell J. Andrews, Leonidas Quintana A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy Russell J. Andrews A5 The role of ...
Source: EPMA Journal - May 8, 2016 Category: Global & Universal Source Type: research

Childhood Body Weight in Relation to Morbidity From Cardiovascular Disease and Cancer in Older Adulthood: 67-Year Follow-up of Participants in the 1947 Scottish Mental Survey.
In conclusion, a relationship between childhood body weight and later morbidity was largely lacking in the present study. PMID: 26443418 [PubMed - as supplied by publisher]
Source: Am J Epidemiol - October 6, 2015 Category: Epidemiology Authors: Batty GD, Calvin CM, Brett CE, Čukić I, Deary IJ Tags: Am J Epidemiol Source Type: research

Childhood Body Weight in Relation to Morbidity From Cardiovascular Disease and Cancer in Older Adulthood: 67-Year Follow-up of Participants in the 1947 Scottish Mental Survey
In conclusion, a relationship between childhood body weight and later morbidity was largely lacking in the present study.
Source: American Journal of Epidemiology - October 23, 2015 Category: Epidemiology Authors: Batty, G. D., Calvin, C. M., Brett, C. E., Cukic, I., Deary, I. J. Tags: RESEARCH-ARTICLE Source Type: research

Intra-hospital correlations among 30-day mortality rates in 18 different clinical and surgical settings
Conclusions</div>The variability in 30-day mortality rates at hospital level and the correlation between risk mortality rates suggest that there may be common hospital-wide factors influencing short-term mortality.</span>
Source: International Journal for Quality in Health Care - January 31, 2017 Category: Global & Universal Source Type: research

Prognosis of Cancer Patients with Aortic Stenosis Under Optimal Cancer Therapies and Conservative Cardiac Treatments.
Authors: Okura Y, Ishigaki S, Sakakibara S, Yumoto C, Hashitate M, Sekine C, Fujita T, Takayama T, Ozaki K, Sato N, Minamino T Abstract Aortic stenosis (AS) is a life-threatening comorbidity of cancer patients. Aortic valve replacement (AVR) should be considered for some cancer patients, but neither the characteristics nor prognosis under conservative therapy is well known.We searched our echocardiography log (years 2005-2014) for cancer patients with AS, and 92 patients (54% female) were included in the study. To compare the survival curves, 470 control patients without AS were selected from our cancer registry.Me...
Source: International Heart Journal - June 9, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

South Africa: North West Health On World Salt Awareness Week
[Govt of SA] The North West Department of Health urge communities to take actions during the World Salt Awareness Week which is marked on 14 - 20 March. The awareness is to educate members of the public that salt can damage their health and it is linked to serious health conditions such as stroke and heart failure. There is also increasing evidence supporting links between our current high salt diets and the onset of stomach cancer, osteoporosis, obesity and kidney stones and kidney disease.
Source: AllAfrica News: Health and Medicine - March 15, 2022 Category: African Health Source Type: news

Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer
We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.Methods: We conducted this retrospective observation study using the JMDC Claims Database and analyzed 55,191 patients with prior history of breast, colorectal, or stomach cancer. The median age was 54 (48 –60) years, and 20,665 participants (37.4%) were men. Using urine dipstick data at baseline, 3,945 and 1,521 participants were categorized as having trace and positive proteinuria...
Source: American Journal of Nephrology - December 21, 2022 Category: Neurology Source Type: research

Pages: 1  2  3  4